New cell therapy targets Hard-to-Treat lupus in early trial
NCT ID NCT07109986
Summary
This is an early-stage study testing a new CAR T-cell therapy called UB-VV410 in adults with severe, treatment-resistant lupus or lupus nephritis (kidney inflammation from lupus). The main goals are to find the safest and most effective dose and to check for side effects. The study will enroll a small group of participants to first test safety and then look for early signs that the treatment might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.